TrialThe Lancet. Haematology2024

Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.

Alexandre Bazinet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.